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Abstract. The high-affinity NGF receptor is thought o 
be a complex of two receptors, gp75 and the tyrosine ki- 
nase TrkA, but direct biochemical evidence for such an 
association has been lacking. In this report, we demon- 
strate the existence of such a gp75-TrkA complex by a 
copatching technique. Gp75 on the surface of intact 
cells is patched with an anti-gp75 antibody and fluores- 
cent secondary antibody, the cells are then fixed to pre- 
vent further antibody-induced redistributions, and the 
distribution of TrkA is probed with an anti-TrkA anti- 
body and fluorescent secondary antibody. We utilize a 
baculovirus-insect cell expression system which allows 
high level expression of wild-type and mutated NGF re- 
ceptors. TrkA and gp75 copatch in both the absence 
and presence of NGF. This association is specific, since 
gp75 does not copatch with other tyrosine kinase recep- 
tors, including TrkB, platelet-derived growth factor re- 
ceptor-~, and Torso (Tor). To determine which do- 
mains of TrkA are required for copatching, we used a 
series of TrkA-Tor chimeric receptors and show that 
the extracellular domain of TrkA is sufficient for co- 
patching with gp75. A chimeric receptor with TrkA 
transmembrane and intracellular domains hows partial 
copatching with gp75. Deletion of the intracellular do- 
main of gp75 decreases but does not eliminate copatch- 
ing. A point mutation which inactivates the TrkA ki- 
nase has no effect on copatching, indicating that this 
enzymatic activity is not required for association with 
gp75. Hence, although interactions between the gp75 
and TrkA extracellular domains are sufficient for com- 
plex formation, interactions involving other receptor 
domains also play a role. 
N 
" GF is an essential neurotrophic factor equired for 
the development, maintenance, and repair of the 
nervous ystem (41). All of the actions of NGF 
are thought o be mediated by two cell surface receptors, 
gp75 and TrkA (1, 5). Gp75 is a 75,000-D glycoprotein 
with a cysteine-rich extracellular domain, a single trans- 
membrane domain and a 155-amino acid cytoplasmic do- 
main (21, 38). It has been suggested that gp75 activates sig- 
nal transduction by interacting with G proteins (10), 
cytoplasmic kinases (51), or by initiating sphingomyelin 
hydrolysis (8). In addition to binding NGF, gp75 binds 
other members of the neurotrophin family (brain-derived 
neurotrophic factor (BDNF), 1 neurotrophin-3 (NT-3), and 
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factor; FRAP, fluorescence r covery after photobleaching; NT-3 and -4, 
neurotrophin-3 and -4; PDGFR-fl, PDGF receptor-B; TGF-I], transform- 
ing growth factor-13. 
neurotrophin-4 (NT-4) (39). The second NGF receptor is 
TrkA, a 140,000-D transmembrane protein with an intra- 
cellular tyrosine-specific kinase domain. Binding of NGF 
activates the TrkA kinase and initiates a signal transduc- 
tion cascade (23, 26). In addition to TrkA, there are two 
other members of the Trk family of receptors, TrkB and 
TrkC. Whereas TrkA preferentially binds NGF, TrkB 
binds both BDNF and NT-4, and TrkC binds NT-3 (1, 5). 
A number of experiments indicate that the two NGF re- 
ceptors interact and synergize with each other. Addition of 
NGF to the developing isthmo-optic nucleus inhibits the 
neurotrophic effects of BDNF and NT-3, presumably by 
competing for binding to gp75 (52). Transgenic mice which 
lack gp75 have neurological deficiencies involving death of 
TrkA-positive sensory neurons (27). Both gp75 and TrkA 
undergo retrograde transport from the synapse to the cell 
body (9, 22, 28). In cell culture models, co-expression of
gp75 enhances the biological response of cells expressing 
TrkA (12, 17, 31, 36, 49). Although Jing et al. (20) report 
that TrkA is sufficient for high-affinity NGF binding, 
Hempstead et al. (14) find that expression of both gp75 
and TrkA is required for high-affinity binding. In addition, 
co-expression of gp75 with TrkA enhances the rate of 
© The Rockefeller University Press, 0021-9525/96/03/945/9 $2.00 
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NGF binding (29). Antibody to gp75 inhibits responses of 
PC12 cells to NGF (2, 4). The synergistic action of these 
receptors has led to the hypothesis that gp75 and TrkA 
form a heteromolecular complex which is the high-affinity 
NGF receptor (14). However, thusfar, chemical cross-link- 
ing and co-immunoprecipitation have yielded only limited 
evidence for the complex (19). 
Since solubilization of membranes with detergent can 
disrupt complexes of membrane proteins (25, 34), co-immu- 
noprecipitation f membrane proteins from detergent ex- 
tracts detects a limited subset of interactions. An alterna- 
tive approach which overcomes this problem is to study 
these interactions i  intact membranes using appropriate 
immunological nd biophysical techniques. For example, 
types II and III TGF-13 receptors how extensive copatch- 
ing on the surface of intact cells, but co-immunoprecipita- 
tion of these receptors f om detergent extracts is slight 
(18). In another case, the association between the erythro- 
cyte anion transporter and glycophorin A was detected by 
measurements of rotational diffusion in intact membranes, 
while the complex failed to be detected by co-immunopre- 
cipitation (33). 
Using fluorescence recovery after photobleaching (FRAP), 
we have measured the lateral diffusion of gp75 in intact 
cells (46, 47, 54). Gp75 is highly mobile on cells which lack 
TrkA and are nonresponsive toNGF. In contrast, gp75 is 
relatively immobilized on TrkA-expressing, NGF-respon- 
sive cells (46). Expression of recombinant TrkA in cells 
lacking endogenous TrkA causes immobilization of gp75, 
even in the absence of NGF (54). These biophysical stud- 
ies demonstrate an interaction between gp75 and TrkA 
supporting, but not proving, the concept of a specific inter- 
molecular complex (14). Furthermore, we were surprised 
to find that the interaction between gp75 and TrkA was 
not synonomous with the display of high-affinity NGF 
binding sites. Gp75(Xba) is a truncated gp75 lacking 
nearly all of the intracellular domain, and TrkA(K538N) 
bears a point mutation which inactivates the tyrosine ki- 
nase domain. Cells expressing gp75(Xba) + TrkA or gp75 
+ TrkA(K538N) receptors have little or no capacity for 
high-affinity binding of NGF (15) (Stephens, R.M., D.R. 
Kaplan, B.L. Hempstead, personal communication). Based 
on analysis of diffusion coefficients, an interaction be- 
tween gp75 and TrkA was detected for cells expressing ei- 
ther gp75(Xba) + TrkA or gp75 + TrkA(K538N). 
In this study, we use copatching, a technique that has 
been used extensively to study interactions between cell 
surface proteins (3, 11, 18), to further test and refine our 
model for NGF receptor structure. In this procedure, addi- 
tion of an antibody directed against a cell surface antigen 
followed by addition of a fluorescent secondary antibody 
results in two-dimensional ggregates or patches on the 
cell surface. The cells are fixed to prevent further anti- 
body-induced redistribution, and an antibody directed 
against a second cell surface antigen is used to determine 
whether that second antigen is included in the patches. To 
facilitate these studies, we have prepared a TrkA-specific 
mAb which binds to the extracellular domain. We find 
that gp75 and TrkA copatch in the absence of added NGF. 
In addition, copatching wasdetected for gp75(Xba)-TrkA 
and gp75-TrkA(K538N). These experiments provide di- 
rect evidence for a gp75-TrkA complex. 
Materials and Methods 
Baculovirus Vectors 
The structures of the receptors used in this study are shown in Fig. 1. Re- 
combinant baculovirus vectors for wild type and mutant human gp75 and 
TrkA and rat TrkB were described previously (44, 54). Recombinant bac- 
ulovirus vectors for Tor (43) and murine PDGF receptor-13 (PDGFR-I3) 
(24) were obtained from D. Morrison (NCI-FCRDC, Frederick, MD). 
Trk/Torso chimeras (trk/tor/tor and tor/trldtrk) were constructed by a 
two-step procedure. First, both human TrkA and Drosophila Torso (a 
generous gift from F. Sprenger, Max-Planck-Institut filr Entwicklungsbi- 
ologie, Tubingen, Germany) cDNAs were mutagenized to introduce a 
unique Mrol restriction site on the extracellular side of the transmem- 
brane sequence region of both receptors. The Mrol site in TrkA was gen- 
erated by mutating amino acids 404 and 405 from lysines to asparagine 
and proline, respectively. The second step in the chimera construction i - 
volved the ligation of respective 5' and 3' halves of the genes to each 
other, tor/tor/trk was constructed by fusing a region of the intracellular 
domains of Torso at the BstE2 site at amino acid 454 with a BspH1 site in 
TrkA at amino acid 463 using Klenow fragment to fill in overhangs gener- 
ated by restriction enzyme digestion. The two fragments were then fused 
in frame to form the full-length chimeric receptor. The TrkA extracellular 
domain construct was generated by PCR to form a molecule with a stop 
codon in the extracellular domain to create a 407-amino acid TrkA pro- 
tein. All three constructs were then cloned into the baculovirus expression 
Figure 1. Schematic  of neurot roph in  receptors: wild type, mu-  
tated, and chimeras. 
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vector pAce4 as Ncol to EcoR1 fragments. TrkA extracellular domain 
was secreted from Sf9 cells infected with the recombinant baculovirus for 
this protein. All three chimeric receptors exhibited ligand-independent ty- 
rosine kinase activity when overexpressed in Sf9 cells. Activity of the trk/ 
tor/tor chimeric receptor could be enhanced by addition of NGF to cells 
expressing this receptor. 
Cell Lines 
Sf9 insect cells were maintained in TMN-FH medium from JRH Bio- 
sciences (Lenexa, KS) supplemented with 9% heat-inactivated fetal bo- 
vine serum and 50 ~g/ml of gentamicin at 28-29°C (45). COS-7 cells were 
maintained in Dulbecco's modified Eagle's medium supplemented with 
10% heat-inactivated fetal bovine serum and 50 I~g/ml of gentamicin. 
Antibodies 
Antibodies against gp75. Two antibodies against gp75 were used in these 
studies. NGFR5, a mouse mAb directed against human gp75, has been de- 
scribed (30). A rabbit serum R7,8 was prepared against he recombinant 
extracellular domain of human gp75 (50). Rabbits were immunized with 
0.4 mg of extracellular domain in complete Freund's adjuvant followed by 
two boosts with 0.5 mg of extracellular domain in incomplete Freund's ad- 
juvant. This antiserum specifically detected gp75 by both immunoprecipi- 
tation and immunofiuorescence labeling of ceils. The specificity of this an- 
tiserum was similar to that of earlier antisera prepared against 
extracellular domains of chick and rat gp75 (53). Antibody from R7,8 anti- 
serum was prepared by affinity chromatography with a protein A column. 
Antibodies against TrkA. Two anti-TrkA antibodies were used in these 
studies. Rabbit antiserum 203 is an anti-pan-Trk reagent directed against 
the Trk COOH terminus (16). The preparation and characterization f 
anti-TrkA mAb, TA-1, is described below. 
Other Antibodies. Antiserum anti-TrkBout is an anti-peptide antibody 
specific for TrkB (residues 76-96). The anti-Torso antibody is a polyclonal 
rabbit antiserum directed against he extracellular domain of Drosophila 
receptor tyrosine kinase, Tor (42), and was provided by F. Sprenger and 
D. Morrison. Antiserum directed against a peptide (residues 1013-1025) 
from human PDGFR-13 was purchased from Upstate Biotechnology Inc. 
(Lake Placid, IVY). Ascites fluid for anti-hemagglutinin monoclonal anti- 
body 12CA5 was purchased from Babco (Richmond, CA). Fluorescein- 
and rhodamine-labeled anti-IgG secondary goat antibodies were ob- 
tained from Fisher Biotech (Springfield, NJ) or Jackson ImmunoResearch 
Laboratories (West Grove, PA). 
Preparation of Anti-TrkA mAb 
COS-7 cells were transfected with the expression vector, pCMV-htrk, en- 
coding the human TrkA receptor (14). At 60 h after transfection, the 
TrkA-expressing COS-7 cells (3 x 106 per mouse) were suspended in Dul- 
becco's PBS and were used to immunize 6-wk-old female BALB/c mice 
(Charles River, Wilmington, MA). Five mice were used per protocol. The 
mice were injected subcutaneously in the lower leg (protocol 1; 50 p.l per 
mouse), in the tail vein (protocol 2; I50 p3) or intraperitoneally (protocol 
3; 500 p~l). They were boosted every third day for 2 wk, using the same 
routes of injection. The mice were bled, and the resulting antisera were 
screened by immunofluorescence, as described below. Two mice from 
protocol 1 and one mouse from protocol 2 were found to express anti- 
TrkA antibodies and were injected by the same routes with 2 × 106 TrkA- 
expressing COS-7 cells every 14 d for 6 wk. 
Cells from the spleen of a protocol 2 mouse and from the popliteal and 
inguinal ymph nodes of a protocol 1 mouse were fused with the nonse- 
creting mouse myeloma variant P3x63Ag-8.653 (2.5 × 107 cells). The fu- 
sion was carried out with 50% (wt/vol) polyethylene glycol in serum-free 
Dulbecco's modified Eagle's medium, as described (13). The resulting 
fused cells were seeded on 96-well plates in medium preconditioned with 
macrophage f eder cells. 
Antisera and hybridoma culture supernatants were screened by immu- 
nofluorescence. Sf9 insect cells were infected with a baculovirus encoding 
TrkA or, as a negative control, with baculoviruses ncoding p75 or TrkB. 
The cells were fixed with 1% paraformaldehyde, blocked with 1 mg/ml of 
BSA, and stained with antisera (diluted 1:50 to 1:1,350) or with undiluted 
hybridoma culture supernatants. Immunoglobulin isotypes were deter- 
mined using a kit from Sigma Chemical Co. (St. Louis, MO). 
Radioiodination and lmmunoprecipitation of Trk 
Extracellular Domains 
The reaction was carried out in a 6 × 50 mm glass tube containing 5 Ixg of 
iodogen (Sigma Chemical Co., St. Louis, MO) dried from chloroform (40). 
2 i~g of the extracellular domain for TrkA, TrkB, or TrkC (35) (gifts from 
A. Welcher) were incubated for 15 min at 4°C with Nal~I (200 i~Ci) in 50 
ixl of 0.15 M NaCI, 0.01 M sodium phosphate, pH 7.5. The protein was sep- 
arated from free label on a PD10 Sephadex G-25 column (Pharmacia Inc., 
Piscataway, NJ). The specific activities of the iodinated proteins ranged 
from 2 × 107 to 6 x 107 cpm/~g. 
40 Ixl of anti-mouse IgG agarose beads (Sigma Chemical Co.) were sus- 
pended for 1 h at 4°C in 500 p~l of 0.5% (vol/vol) NP-40, 140 mM NaCI, 10 
mM Trizma, 10 mM NaF, 5 mM Na2EDTA, and 100 Kallikrein IU/ml of 
aprotinin supplemented with either 10 ~1 of TA-1 ascites fluid or 10 p.1 of 
12CA5 ascites fluid. The beads were washed twice with the same buffer. 
Trk extracellular domains (100,000 cpm) were incubated for 2 h at 4°C 
with the beads. The beads were washed three times and boiled in SDS 
sample buffer with 2-mercaptoethanol. The samples were analyzed by 
SDS-PAGE with a 10% gel followed by autoradiography for8-22 h. 
BacuIovirus Expression i  Sf9 Cells 
To express a single NGF receptor, recombinant baculovirus was added to 
Sf9 cells (2 × 106 ceils in a 25-cm 2 flask) at a multiplicity of infection 
(m.o.i.) of 1 for the gp75 virus or a m.o.i, of 4 for TrkA. For coexpression 
experiments, TrkA baculovirus was added to Sf9 cells at a m.o.i, of 16 fol- 
lowed by immediate addition of gp75 baculovirus at m.o.i, of 1. Infections 
with the Tor or PDGFR-I~ baculoviruses were done in the same manner as 
TrkA. Experiments were carried out 60-h postinfection. 
TrkA extracellular domain was produced in the baculovirus Sf9 system 
using procedures described previously (50). The extracellular domain was 
purified by TA-1 immunoaffinity chromatography and by ion-exchange 
chromatography on a MONO-Q column (Pharmacia, Piscataway, N J). 
Copatching Assay 
Cells were incubated for 30 min at room temperature with an antibody di- 
rected against one of the recombinant receptor proteins expressed by the 
St9 cells. The cells were pelleted (100 g for 4 min) and washed twice with 
200 ixl of Sf9 medium. The cells were suspended in St x) medium with a flu- 
orescein- or rhodamine-labeled anti-IgG antibody. The cells were pel- 
leted, washed twice and fixed for 10 min at 4°C shielded from light, using a 
fresh solution of 1% glutaraldehyde in Dulbecco's PBS. The ceils were 
washed twice and incubated for 30 min at room temperature with an anti- 
body directed against he other recombinant receptor protein. The ceils 
were washed twice and incubated with a fluorescently abeled secondary 
antibody and washed again. 
For the copatching experiments, the primary antibodies were used at 
the following dilutions or concentrations: R7,8 antibody, 0.18 mg/ml; 
NGFR5 antibody, 0.01 mg/ml; TA-1 ascites, 1:100; 203 antiserum, 1:400; 
anti-Tor antiserum, 1:50; anti-PDGFR-13 antiserum, 1:50. Secondary fluo- 
rescein- and rhodamine-labeled antibodies were used at 40-75 pLg/ml. 
Copatching was screened on a Zeiss Axiovert microscope using an oil 
immersion 100x planapochromat objective (NA = 1.4) under 100 W Hg 
illumination. Fluorescein and rhodamine were visualized using Carl Zeiss 
909 and 914 filter cubes, respectively. Cells for which >50% of the patches 
exhibited both fluorescein and rhodamine fluorescence were scored as 
positive. Although the choice of 50% is arbitrary, the scoring is not greatly 
affected by this parameter. Most cells are either nearly completely co- 
patched or not copatched at all. Hence, for most ceils, setting the cut-off at 
25, or 50, or 75% would not change the basic results. In each experiment, 
~100 cells were assessed for copatching. 
Confocal Microscopy 
Photomicrographs were obtained using a Bio-Rad Laboratories (Her- 
cules, CA) MRC 1003 scanhead on a Nikon 200 Diavert microscope using 
a 60× planapochromatic o l immersion objective (NA = 1.4). The confo- 
cal was operated in the two color mode using the T1-Triple Dichroic and 
TA2-D560 DRLP filter blocks. All images were taken at a zoom setting of 
3.2 using slit widths of 2.4-3.0 ram, Kahlman averaging over 20 frames. 
Images were contrast stretched and then local contrast enhanced. Col- 
lected images were colorized using Universal Imaging Metamorph 
(Westchester, PA) software, and fluorescein and rhodamine images were 
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merged together. In these combined images, areas of copatching are yel- 
low. The individual and merged images were assembled into montages 
with CorelDraw (Ontario, Canada) and ultimately printed with a Kodak 
8600 dye sublimation color printer. 
Results 
Preparation and Characterization of Anti-TrkA mAb 
To perform these experiments, it was necessary to produce 
an antibody specific to the extracellular domain of TrkA. 
Mice were immunized with TrkA-expressing COS-7 cells 
as described in the Materials and Methods. An IgG3-pro- 
ducing hybridoma, TA-1, was selected and found to immu- 
nostain TrkA-expressing Sf9 cells, but not TrkB- or gp75- 
expressing Sf9 cells (Fig. 2, C and D, not shown for TrkB). 
In contrast, the anti-gp75 rabbit antiserum R7,8 stained 
gp75-expressing cells and not TrkA-expressing cells (Fig. 
2, A and B). TA-1 also stained TrkA-expressing COS-7 
cells (not shown) and cholinergic neurons in rat brain sec- 
tions (28). TA-1 immunoprecipitated heTrkA extracellu- 
lar domain but not the TrkB or TrkC extracellular do- 
mains (Fig. 3). The epitope for TA-1 appears to be 
conformation dependent and distinct from the NGF-bind- 
ing site, since this mAb did not stain TrkA in Western blot- 
ting analyses and did not block the effects of NGF on PC12 
cells (not shown). To our knowledge, this is the first TrkA- 
specific mAb to be reported, although there is a TrkA- 
specific rabbit antiserum (6). 
Copatching Studies 
In this paper, we exploit patching by antibodies R7,8 and 
TA-1 (Fig. 2) to demonstrate a heteromolecular complex. 
The fundamental paradigm of these copatching experi- 
ments is to label and patch gp75 on the cell surface, to fix 
the cells to prevent further redistributions, and then to 
stain TrkA by immunofluorescence in a second color. 
It was first necessary to determine fixation conditions 
which effectively eliminate antibody-induced patching. 
Noncross-linking fixatives such as paraformaldehyde o 
Figure 2. Specificities of R7,8 and TA-1 antibodies. Sf9 cells in- 
fected with a baculovirus encoding gp75 (A and C) or encoding 
TrkA (B and D) were immunostained with anti-gp75 antibody 
R7,8 (0.18 mg/ml) (A and B) or anti-TrkA mAb TA-1 (ascites 
1:100) (C and D). As shown in A, gp75-expressing cells stain pos- 
itively with R7,8, and TrkA-expressing cells stain with TA-1. 
Figure 3. mAb TA-1 immu- 
noprecipitates the TrkA. 
Radioiodinated TrkA extra- 
cellular domain, TrkB extra- 
cellular domain a d TrkC ex- 
tracellular domain (100,000 
cpm/sample) were ither di- 
rectly applied to the SDS- 
polyacrylamide gel or first 
immunoprecipitated with 
mAb TA-1 and then analyzed. TrkA extracellular domain, but
not TrkB or TrkC extracellular domain, was immunoprecipi- 
tated. TrkA extracellular domain was not immunoprecipitated 
by control mAb 12CA5. 
not immobilize surface proteins and do not prevent redis- 
tributions (32). Sf9 cells coexpressing gp75 and TrkA were 
fixed with 0.1-1.0% glutaraldehyde aswell as mixtures of 
glutaraldehyde and paraformaldehyde. They were then la- 
beled sequentially with R7,8 antibody, rhodamine goat 
anti-rabbit IgG, TA-1 antibody, and fluorescein goat anti- 
mouse IgG. Pressure from the coverslip slightly flattened 
the cells, thereby, presenting a large flat surface suitable 
for observation with the confocal microscope. We ulti- 
mately selected fixation of cells with 0.75% glutaraldehyde 
in Dulbecco's PBS for 10 min in the dark at 4°C because 
this was the lowest concentration f glutaraldehyde which 
consistently prevented redistribution of antigens (Fig. 4, 
A-C). Use of glutaraldehyde resulted in some autofluores- 
cence, particularly in the cytoplasm. However, because au- 
tofluorescence was weaker at the surface of the cell and 
immunostaining of the baculovirus-infected Sf9 cells was 
strong, scoring of copatching was not hindered. 
Fig. 4 (D-F) show a typical copatching experiment. Sf9 
cells expressing both gp75 and TrkA were incubated with 
R7,8 anti-gp75 antibody followed by rhodamine anti-rab- 
bit IgG, fixed, and then labeled with anti-TrkA mAb TA-1 
followed by fluorescein anti-mouse IgG. Using the confo- 
cal microscope, we observed extensive co-localization of 
TrkA and gp75 (Fig. 4, D-F). In the merged images (Fig. 
4, C, F, and/), areas of copatching are yellow. 
Several possible artifacts were considered. The cross- 
linking experiment was repeated, using a fluorescein sec- 
ondary antibody for gp75 and rhodamine secondary anti- 
body for TrkA. The results were essentially identical to 
those shown in Fig. 4 (D-F), demonstrating that filter 
bleedthrough was not a problem. Also, since omission of 
either primary antibody resulted in neglible staining with 
the corresponding secondary antibody, there was no cross- 
reactivity of the secondary antibodies. For cells expressing 
gp75 but not TrkA, gp75 patches were detected, but no 
TrkA staining was detected. For cells expressing TrkA but 
not gp75, gp75 staining was not detected and TrkA stain- 
ing was uniform. Copatches were additionally observed 
using anti-gp75 mAb NGFR5 and a different anti-Trk an- 
tiserum, 203. Copatches also were observed if TrkA was 
patched with mAb TA-1, the cells were fixed and gp75 was 
detected with R7,8 antibody. Hence, the immunostaining 
in these experiments was specific, and the copatching oc- 
curred using several different anti-NGF receptor antibod- 
ies and labeling protocols. 
To quantitate these results, we scored the Sf9 cells for 
copatching (Fig. 5, see Materials and Methods for details). 
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Figure 4. Confocal photomicrographs s owing copatching of TrkA, but not Tor, with gp75. A-C  show the lack of patching when cells 
were first fixed with 0.75% glutaraldehyde and subsequently labeled for gp75 (A) and TrkA (B). The sum of images A and B is shown in 
C, as described in Materials and Methods. This result demonstrates the effectiveness of 0.75% glutaraldehyde in preventing antibody- 
induced patching. (D-F) show copatching ofTrkA (E) with gp75 (D) and the combined image (F). gp75 was labeled and patched with 
R7,8 (0.18 mg/ml) followed by rhodamine goat anti-rabbit IgG. The cells were then fixed with 0.75 % glutaraldehyde, and the TrkA was 
labeled with TA-1 (ascites 1:100) followed by fluorescein goat anti-mouse IgG. A very high degree of copatching (yellow in F) is ob- 
served. G-I  show the lack of copatching for gp75 (G) and Tor (H). Cells were treated as in D-F  except hat gp75 was patched and la- 
beled with NGFR5 (0.01 mg/ml) followed by fluorescein goat anti-mouse IgG. Following fixation of the cells, Tor was labeled with anti- 
Tor rabbit serum (1:50) followed by rhodamine goat anti-rabbit IgG. The combined image (/) shows both red and green areas indicating 
a lack of copatching. Bar, 5 Ixm. 
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Figure 5. Quantitative assay of copatching. (A) Gp75 copatches 
with TrkA but not with other receptor tyrosine kinases. (B) Co- 
patching between modified forms of gp75 and TrkA. TrkA co- 
patches with wild-type gp75 and a truncated receptor, gp75(Xba). 
TrkA(K538N) which bears an inactive kinase domain copatches 
with gp75. Addition of NGF does not enhance copatching. (C) 
Copatching of gp75 with TrkA-Tor chimeric receptors. The ex- 
tracellular, transmembrane and intracellular domains of TrkA 
play a role in formation of the gp75-TrkA complex, but the ex- 
traceUular domain of TrkA apparently has the largest role. De- 
tails of these xperiments are given in the text. Gp75 was patched 
using either mAb NGFR5 (0.01 mg/ml) (solid bars) or rabbit an- 
tibody R7,8 (0.18 mg/ml) (cross-hatched bars). The rabbit anti- 
body was visualized with a rhodamine anti-rabbit IgG and the 
mAb with a fluorescein anti-mouse IgG. The Trk or other ty- 
rosine kinase receptor was then labeled with the other species 
(rabbit/mouse) of primary antibody and the other color (rhodamine/ 
fluorescein) secondary antibody. Data are given as mean _+ SEM. 
Averaging eighteen experiments of the type shown in Fig. 
4 (D-F) (R7,8 and TA-1 antibodies), we found that 85 _ 
3% (n = 18) of the cells were copatched. Similar results 
(82 - 2% of cells, n = 6) were obtained using mAb 
NGFR5 for gp75 and rabbit antibody 203 against TrkA. 
Several other receptor kinases were co-expressed with 
gp75 and found to give very low levels of copatching: TrkB 
(6 ___ 1%, n = 6), PDGFR-13 (12 ~ 2%, n = 5), and Dro- 
sophila protein Tor (5 --- 4%, n = 5). All of these values 
are significantly less than that for TrkA (P ~< 0.0005 by the 
t test). Fig. 4 (G-/)  shows a cell expressing p75 and Tor. 
The R7,8 anti-gp75 antibody resulted in patching of gp75, 
but there is little or no copatching of Tor. 
Results of our previous tudy (54) using FRAP demon- 
strated that a mutant form of gp75 which lacks its cytoplas- 
mic domain, gp75(Xba), interacts with wild-type TrkA and 
similarly that a kinase-deficient TrkA mutant TrkA(K538N) 
interacts with wild-type gp75. These findings were tested 
using the copatching assay (Fig. 5 B). The gp75(Xba) re- 
ceptor copatched with TrkA, albeit at a reduced level 
(53 ___ 2% of cells, n = 6, P <~ 0.01) but still significantly 
greater than the negative controls (P ~< 0.0005). TrkA 
(K538N) was as effective as wild-type TrkA in copatching 
with gp75 (79 ___ 2%, n = 4). Hence, the copatching results 
confirm the interactions uggested by the the earlier 
FRAP experiments. 
Additionally, we tested by copatching (Fig. 5 B) whether 
gp75-TrkA interactions are enhanced by the presence of 
NGF. Sf9 cells expressing p75 and TrkA were incubated 
with 100 nM of NGF for 15 min. Then the copatching as- 
say was carried out, including NGF with the R7,8 anti- 
gp75 antibody and the rhodamine anti-rabbit IgG anti- 
body. Copatching in the presence of NGF (79 _ 2% of 
cells, n = 5) was similar to the NGF-minus result. It was 
possible that NGF did not enhance gp75-TrkA copatching 
because the level of copatching was already maximal. 
Hence, we tested whether NGF enhances copatching of 
gp75(Xba)-TrkA and found 55 4- 5% (n = 3) of cells co- 
patched. The plus-NGF and the minus-NGF results for co- 
patching are not statistically different, demonstrating that 
NGF does not significantly influence this interaction. 
To determine which domains of TrkA are required for 
copatching with gp75, we studied a series of chimeric re- 
ceptors derived from TrkA and Tor (Fig. 5 C). We chose 
Tor for these studies because Tor and TrkA have the same 
overall structure (extracellular NHE terminus, single trans- 
membrane domain and intracellular kinase domain), but 
the sequences of the two receptors are not closely homolo- 
gous. As discussed above, the wild-type Tor (tor/tor/tor 
which has Tor extracellular, transmembrane and intracel- 
lular domains) exhibited copatching for 5 __+ 4% (n = 5) of 
the ceils. Substitution of the intracellular TrkA domain for 
the Tor intracellular domain (tor/tor/trk) led to 16 --- 3% 
(n = 6) of cells copatched, only slightly higher than tor/tor/ 
tor (P ~< 0.05) and significantly lower than wild-type trk/ 
trk/trk (P <~ 0.0005). For the tor/trk/trk chimera, 26 _+ 8% 
(n = 10) of cells were copatched, again higher than tor/tor/ 
tor (P ~< 0.025) and significantly lower than trk/trk/trk 
(P ~< 0.0005). In contrast, the trk/tor/tor chimera formed 
copatches with gp75 for 84 _+ 1% (n = 4) of the cells which 
is statistically equivalent to trk/trk/trk. Thus, although the 
intracellular and transmembrane domains of TrkA can in- 
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duce a complex with gp75, the extracellular domain of 
TrkA appears to dominate this interaction. 
To further examine the role of the TrkA extracellular 
domain in copatching with gp75, we considered whether 
soluble TrkA-extracellular domain would compete with 
membrane-bound TrkA for binding to gp75. We prepared 
a soluble TrkA-extracellular domain using the baculovirus 
insect cell system (see Materials and Methods). Fig. 6 D 
shows that by SDS-PAGE the 64,000-D extracellular do- 
main is >90% pure. The molecular weight of this TrkA 
extracellular domain which was prepared in insect cells 
(see Materials and Methods) was less than that for the ex- 
tracellular domain prepared in CHO cells (Fig. 3). This 
difference is presumably due to decreased glycosylation i
the insect cells. 
Recombinant TrkA-extracellular domain was included 
with the anti-gp75 antibody R7,8 and the rhodamine anti- 
rabbit IgG secondary antibody. The cells were then fixed 
and stained with anti-TrkA mAb TA-1 and the fluorescein 
anti-mouse IgG secondary antibody (Fig. 6, A-C) .  Since 
gp75-expressing Sf9 cells incubated with TrkA extracellu- 
lar domain did not stain with anti-TrkA mAb (not shown), 
the staining in the copatching experiment was specific for 
the membrane-bound TrkA and not for TrkA extracellu- 
lar domain that might be nonspecifically adhering to the 
cells. The presence of the TrkA-extracellular domain re- 
duced the l vel of gp75-TrkA copatching to 51 _ 9% (n = 
5) (P ~< 0.005) (Fig. 6 E). Therefore, the gp75-TrkA com- 
plex detected by copatching results from a saturable inter- 
action at the cell surface. 
Discussion 
In this study of NGF receptor complexes, we use a co- 
patching technique which in many regards is the two- 
dimensional nalogue of immunoprecipitation. In particular, 
associations with other cellular components are expected 
to remain intact under the experimental conditions for co- 
patching. Using monoclonal and polyclonal anti-NGF re- 
ceptor antibodies, we detected copatching and, therefore, 
intermolecular complexes of gp75 and TrkA on the sur- 
face of Sf9 insect cells. The use of the baculovirus insect 
cell system greatly aided these studies by allowing rapid, 
high level expression of these receptors. Analysis of other 
Figure 6. Soluble TrkA extracellular domain inhibits gp75-TrkA copatching. Copatching was carried out as described in the text in the 
presence or absence of 0.1 mg/ml of TrkA extracellular domain. Immunostaining for gp75 with rabbit antibody R7,8 (0.18 mg/ml) fol- 
lowed by rhodamine anti-rabbit IgG (A), TrkA with mAb TA-1 (ascites 1:100) followed by fluorescein anti-mouse IgG (B) and the 
combined images (C) are shown for a cell which did not copatch. (D) Analysis of the TrkA extracellular domain (3 i~g/lane) by SDS- 
polyacrylamide g l electrophoresis and Coomassie blue staining showing the purity of the recombinant protein. (E) Quantitation fco- 
patching showing mean _ SEM. Bar, 5 I~m. 
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receptors as well as mutated NGF receptors demonstrated 
that this interaction is specific. The simplest model to ex- 
plain our earlier FRAP data (54) and the current experi- 
ments is a heterocomplex of gp75 and TrkA as proposed 
by Hempstead et al. (14). The characteristics of this com- 
plex are that (1) it is not dependent on the presence of 
NGF, (2) the extracellular domains drive complex forma- 
tion, (3) the complex is not dependent upon the existence of 
high-affinity NGF binding sites (15) (Stephens, R.M., D.R. 
Kaplan, and B.L. Hempstead, personal communication). 
The copatching is likely to reflect a specific interaction 
between gp75 and TrkA, since PDGFR-[3, Tor and TrkB 
do not copatch with gp75. Since TrkA and TrkB are 
closely homologous, the experiments with gp75 and TrkB 
are particularly cogent. Additionally, the inhibition of co- 
patching by soluble TrkA extracellular domain demon- 
strates a specific, saturable interaction on the cell surface. 
Since use of the baculovirus insect cell system leads to 
elevated levels of receptor expression, a reasonable ques- 
tion is whether we can extrapolate these conclusions to 
neuronal cells with lower levels of receptor expression. 
For instance, Ventura et al. (48) reported that TGF-[3 re- 
ceptors I and II normally form a complex only in the pres- 
ence of TGF-IL These receptors overexpressed in insect 
cells associate in the absence of TGF-[3. However, our pre- 
vious results using FRAP indicate that the interaction be- 
tween gp75 and TrkA in the absence of NGF is not related 
to the higher levels of expression. Interaction between 
gp75 and TrkA consistent with an intermolecular complex 
is readily detected in PC12 pheochromocytoma cells and 
sensory neurons, even in absence of NGF (46, 54). We 
have so far been unable to extend these copatching studies 
to PC12 cells. The lower levels of NGF receptors ex- 
pressed in these cells render it difficult to distinguish spe- 
cific labeling from the glutaraldehyde autofluorescence. In 
addition, the TrkA receptor was difficult to patch with 
anti-TrkA antibody, perhaps due to additional interac- 
tions of TrkA in the PC12 membrane. Therefore, the Sf9 
cells provide a model well suited for the copatching tech- 
nique, and the conclusions of the current study are likely 
to be applicable to neuronal cell types. 
In this study, we did not observe copatching between 
gp75 and TrkB. However, using FRAP, we previously ob- 
served a slight but statistically significant interaction (54). 
Furthermore, Hantzopoulos et al. (12) observed a func- 
tional synergy between gp75 and TrkB receptors ex- 
pressed on fibroblasts. Hence, these two receptors may 
form a weakly bound and, perhaps, shortlived complex. 
The functional synergy between gp75 and TrkB (12) might 
result from this complex, or gp75 and TrkB might act as in- 
dependent receptors emitting synergistic signals (8, 37). 
These data lead to an apparent, possibly informative 
contradiction. The studies with chimeric receptors demon- 
strate that the NGF receptor extracellular domains are 
sufficient for the interaction between gp75 and TrkA. 
However, mutations of the gp75 and TrkA intracellular 
domains affect NGF binding (15) (Stephens, R.M., D.R. 
Kaplan, and B.L. Hempstead, personal communication). 
If these mutations do not affect formation of a gp75-TrkA 
complex, then why do they alter NGF binding affinity? 
We suggest wo possible models to resolve this contra- 
diction. The first is based on allosteric enzymes. For this 
type of regulation, a compound binds to the protein at a 
distance from the active site. The compound induces a 
conformational change, frequently involving a small shift 
in the angle between subunits (7). Although the change in 
structure is small, the effect on activity can be quite large. 
Such allosteric regulation might be relevant to the affinity 
of NGF binding. While gp75 and TrkA can form a com- 
plex via their extraceUular domains, the conformation of 
the complex and, therefore, its affinity for NGF might be 
affected at a distance by the intracellular domains. Muta- 
tions of the intracellular domains may induce a slight rota- 
tion of the extracellular domains, thereby, modulating 
binding affinity for NGF. In the second model, we propose 
a third subunit which interacts with gp75 and TrkA 
through the intracellular domains and is required for high- 
affinity NGF binding. Since our earlier FRAP study (54) 
demonstrated a correlation between high-affinity NGF 
binding and immobilization of gp75, interactions with this 
third subunit also might result in immobilization of the 
gp75-TrkA complex. 
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